Company profile: Atara Biotherapeutics
1.1 - Company Overview
Company description
- Provider of off-the-shelf, allogeneic T-cell immunotherapies, conducting clinical studies to evaluate safety and efficacy; offering expanded access to investigational drugs for treatment use; providing educational grants in T-cell immunotherapy; and supplying healthcare providers with information on products and clinical application.
Products and services
- Information for Healthcare Providers: Supplies healthcare professionals with information about Atara’s allogeneic T-cell immunotherapy products and their clinical application
- Expanded Access: Offers a pathway for patients with serious diseases or conditions to gain access to Atara’s off-the-shelf investigational drugs for treatment use
- Clinical Studies: Conducts clinical studies to evaluate the safety and efficacy of Atara Biotherapeutics’ allogeneic T-cell immunotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atara Biotherapeutics
U-Systems
HQ: United States
Website
- Description: Provider of automated breast ultrasound systems and software that deliver automated breast scans to assist radiologists in detecting breast cancer, particularly in women with dense breast tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U-Systems company profile →
Highlight Therapeutics
HQ: Spain
Website
- Description: Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Highlight Therapeutics company profile →
Clarient
HQ: United States
Website
- Description: Provider of cancer diagnostic testing and oncology diagnostic services in the United States, partnering with local pathologists and oncologists to bring the standard of care back to their communities, using multiple technologies to clarify complex problems, help diagnose cancer cases, and provide insight.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarient company profile →
Secretome Therapeutics
HQ: United States
Website
- Description: Provider of neonatal mesenchymal stem cell-based therapeutics and secretome-based regenerative therapies for heart failure and neurodegenerative and dermatological diseases, including STM-01 for adult and pediatric heart failure and NEO2001 for chronic ischemic heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Secretome Therapeutics company profile →
NuView Life Sciences
HQ: United States
Website
- Description: Provider of medical imaging and diagnostic solutions leveraging the NV-VPAC1 peptide to target VPAC1 receptors for PET imaging and theranostic applications. Offers in vitro urine-based diagnostic kits for detecting prostate and bladder cancer, in vivo PET agents for diagnosing breast and prostate cancer, and peptide-guided delivery of isotopes (e.g., Copper-64 for imaging, Copper-67 for treatment).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuView Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atara Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atara Biotherapeutics
2.2 - Growth funds investing in similar companies to Atara Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atara Biotherapeutics
4.2 - Public trading comparable groups for Atara Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →